Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18559720rdf:typepubmed:Citationlld:pubmed
pubmed-article:18559720lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:18559720lifeskim:mentionsumls-concept:C0018801lld:lifeskim
pubmed-article:18559720lifeskim:mentionsumls-concept:C0020538lld:lifeskim
pubmed-article:18559720lifeskim:mentionsumls-concept:C0155626lld:lifeskim
pubmed-article:18559720lifeskim:mentionsumls-concept:C0262926lld:lifeskim
pubmed-article:18559720lifeskim:mentionsumls-concept:C0961485lld:lifeskim
pubmed-article:18559720lifeskim:mentionsumls-concept:C0332119lld:lifeskim
pubmed-article:18559720lifeskim:mentionsumls-concept:C0231242lld:lifeskim
pubmed-article:18559720pubmed:issue2lld:pubmed
pubmed-article:18559720pubmed:dateCreated2008-7-24lld:pubmed
pubmed-article:18559720pubmed:abstractTextIn the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (n=6632), eplerenone-associated reduction in all-cause mortality was significantly greater in those with a history of hypertension (Hx-HTN). There were 4007 patients with Hx-HTN (eplerenone: n=1983) and 2625 patients without Hx-HTN (eplerenone: n=1336). Propensity scores for eplerenone use, separately calculated for patients with and without Hx-HTN, were used to assemble matched cohorts of 1838 and 1176 pairs of patients. In patients with Hx-HTN, all-cause mortality occurred in 18% of patients treated with placebo (rate, 1430/10 000 person-years) and 14% of patients treated with eplerenone (rate, 1058/10 000 person-years) during 2350 and 2457 years of follow-up, respectively (hazard ratio [HR]: 0.71; 95% CI: 0.59 to 0.85; P<0.0001). Composite end point of cardiovascular hospitalization or cardiovascular mortality occurred in 33% of placebo-treated patients (3029/10 000 person-years) and 28% of eplerenone-treated patients (2438/10 000 person-years) with Hx-HTN (HR: 0.82; 95% CI: 0.72 to 0.94; P=0.003). In patients without Hx-HTN, eplerenone reduced heart failure hospitalization (HR: 73; 95% CI: 0.55 to 0.97; P=0.028) but had no effect on mortality (HR: 0.91; 95% CI: 0.72 to 1.15; P=0.435) or on the composite end point (HR: 0.91; 95% CI: 0.76 to 1.10; P=0.331). Eplerenone should, therefore, be prescribed to all of the post-acute myocardial infarction patients with reduced left ventricular ejection fraction and heart failure regardless of Hx-HTN.lld:pubmed
pubmed-article:18559720pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18559720pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18559720pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18559720pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18559720pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18559720pubmed:languageenglld:pubmed
pubmed-article:18559720pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18559720pubmed:citationSubsetIMlld:pubmed
pubmed-article:18559720pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18559720pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18559720pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18559720pubmed:statusMEDLINElld:pubmed
pubmed-article:18559720pubmed:monthAuglld:pubmed
pubmed-article:18559720pubmed:issn1524-4563lld:pubmed
pubmed-article:18559720pubmed:authorpubmed-author:AliAhmedAlld:pubmed
pubmed-article:18559720pubmed:authorpubmed-author:ShiHarryHlld:pubmed
pubmed-article:18559720pubmed:authorpubmed-author:PittBertramBlld:pubmed
pubmed-article:18559720pubmed:authorpubmed-author:KrumHenryHlld:pubmed
pubmed-article:18559720pubmed:authorpubmed-author:ZannadFaiezFlld:pubmed
pubmed-article:18559720pubmed:authorpubmed-author:AschermannMic...lld:pubmed
pubmed-article:18559720pubmed:authorpubmed-author:ParkhomenkoAl...lld:pubmed
pubmed-article:18559720pubmed:authorpubmed-author:LoveThomas...lld:pubmed
pubmed-article:18559720pubmed:authorpubmed-author:NicolauJoseJlld:pubmed
pubmed-article:18559720pubmed:authorpubmed-author:SolomonHenryHlld:pubmed
pubmed-article:18559720pubmed:authorpubmed-author:CardosoJosé...lld:pubmed
pubmed-article:18559720pubmed:authorpubmed-author:CorbalánRamon...lld:pubmed
pubmed-article:18559720pubmed:issnTypeElectroniclld:pubmed
pubmed-article:18559720pubmed:volume52lld:pubmed
pubmed-article:18559720pubmed:ownerNLMlld:pubmed
pubmed-article:18559720pubmed:authorsCompleteYlld:pubmed
pubmed-article:18559720pubmed:pagination271-8lld:pubmed
pubmed-article:18559720pubmed:dateRevised2010-8-20lld:pubmed
pubmed-article:18559720pubmed:meshHeadingpubmed-meshheading:18559720...lld:pubmed
pubmed-article:18559720pubmed:meshHeadingpubmed-meshheading:18559720...lld:pubmed
pubmed-article:18559720pubmed:meshHeadingpubmed-meshheading:18559720...lld:pubmed
pubmed-article:18559720pubmed:meshHeadingpubmed-meshheading:18559720...lld:pubmed
pubmed-article:18559720pubmed:meshHeadingpubmed-meshheading:18559720...lld:pubmed
pubmed-article:18559720pubmed:meshHeadingpubmed-meshheading:18559720...lld:pubmed
pubmed-article:18559720pubmed:meshHeadingpubmed-meshheading:18559720...lld:pubmed
pubmed-article:18559720pubmed:meshHeadingpubmed-meshheading:18559720...lld:pubmed
pubmed-article:18559720pubmed:meshHeadingpubmed-meshheading:18559720...lld:pubmed
pubmed-article:18559720pubmed:meshHeadingpubmed-meshheading:18559720...lld:pubmed
pubmed-article:18559720pubmed:meshHeadingpubmed-meshheading:18559720...lld:pubmed
pubmed-article:18559720pubmed:meshHeadingpubmed-meshheading:18559720...lld:pubmed
pubmed-article:18559720pubmed:meshHeadingpubmed-meshheading:18559720...lld:pubmed
pubmed-article:18559720pubmed:meshHeadingpubmed-meshheading:18559720...lld:pubmed
pubmed-article:18559720pubmed:meshHeadingpubmed-meshheading:18559720...lld:pubmed
pubmed-article:18559720pubmed:meshHeadingpubmed-meshheading:18559720...lld:pubmed
pubmed-article:18559720pubmed:meshHeadingpubmed-meshheading:18559720...lld:pubmed
pubmed-article:18559720pubmed:meshHeadingpubmed-meshheading:18559720...lld:pubmed
pubmed-article:18559720pubmed:meshHeadingpubmed-meshheading:18559720...lld:pubmed
pubmed-article:18559720pubmed:meshHeadingpubmed-meshheading:18559720...lld:pubmed
pubmed-article:18559720pubmed:meshHeadingpubmed-meshheading:18559720...lld:pubmed
pubmed-article:18559720pubmed:year2008lld:pubmed
pubmed-article:18559720pubmed:articleTitleHistory of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure.lld:pubmed
pubmed-article:18559720pubmed:affiliationUniversity of Michigan, 1500 E Medical Center Dr, 3910 Taubman Center, Ann Arbor, MI 48109-0366, USA. bpitt@med.umich.edulld:pubmed
pubmed-article:18559720pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18559720pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:18559720pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:18559720pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:18559720pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18559720lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18559720lld:pubmed